ClinicalTrials.gg
TerminatedNCT05674448Updated Oct 10, 2023

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

A Phase 2 interventional study of HH-003 20mg/kg and HH-003 3mg/kg in Chronic Hepatitis B and Hepatitis D Co-infection, sponsored by Huahui Health. Terminated at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Huahui Health · Phase 2, Interventional, and Treatment

Why this study was terminated
During the study, the sponsor adjusted the overall clinical development strategy, decided to terminate the enrollment in advance after discussion with the lead investigator.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Aug 2021, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
267th of 273
9 · median 120
Started
2021
with 24 others
Phase 2
72 of 375
15 open now
Registered
252nd of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 267th largest by enrollment of the 273 interventional ones that give a count, is one of 25 that started in 2021, is one of 72 in phase 2, and was the 252nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This is an open-label phase IIa study of HH-003 to evaluate its antiviral activity and safety in subjects with chronic hepatitis B and hepatitis D co-infection. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV/HDV.

03

Conditions studied

  • Chronic Hepatitis B and Hepatitis D Co-infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form;
  • Male or female subjects aged from 18 to 70 years inclusively;
  • 18 kg/m2≤≤32 kg/m2, body weight ≥45 kg for men and ≥40 kg for women;
  • Positive , anti-HDV IgG antibody and HDV RNA at screening;
  • Women of or male subjects with female partners of childbearing potential should agree to use an adequate and highly effective contraceptions from screening to the end of study or until 12 weeks after last dose of the study drug (whichever is longer).

Exclusion criteria

Exclusion Criteria:

  • Be pregnant or lactating at screening;
  • Subjects with decompensated liver cirrhosis;
  • Subjects with liver dysfunction (including but not limited to ascites, hepatic encephalopathy and upper gastrointestinal bleeding) within 3 months prior to screening;
  • Average daily alcohol consumption >40g for men and >20g for women or drug abuse within 6 months prior to screening;
  • Subjects with other serious diseases that is inappropriate for study participation per the Investigator's or the Sponsor's discretion (including but not limited to serious cardiac or pulmonary disease, chronic or recurrent urinary disorders, uncontrolled diabetes and diseases, epilepsy requiring treatment);
  • History of hepatocellular carcinoma (HCC) or hepatocellular carcinoma suggested by liver histopathology or liver imaging;
  • Interferon antiviral therapy within 1 year prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    HH-003 20mg/kg

    HH-003 20mg/kg, intravenously, Q2W

    Biological: HH-003 20mg/kg

  • Experimental
    HH-003 3mg/kg

    HH-003 3mg/kg, intravenously, Q2W

    Biological: HH-003 3mg/kg

Interventions

  • BiologicalHH-003 20mg/kg

    Drug page: Libevitug

    HH-003 20mg/kg Q2W intravenously for 24 weeks

  • BiologicalHH-003 3mg/kg

    Drug page: Libevitug

    HH-003 3mg/kg Q2W intravenously for 24 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with HBV DNA Negativation or Decrease by ≥1 log10 from Baseline at Week 24

    Time frame: Week 24

  2. Percentage of Participants with HDV RNA Negativation or Decrease by ≥1 log10 from Baseline at Week 24

    Time frame: Week 24

  3. Change from Baseline in Serum HBsAg Levels at Week 24

    Time frame: from baseline to Week 24

Secondary outcomes

  1. Percentage of participants with ALT normalization at week 24

    Time frame: Week 24

  2. Changes from Baseline in Serum HBsAg Levels during the Study Period

    Time frame: from baseline to Week 48

  3. Changes from Baseline in Serum HBV RNA Levels during the Study Period

    Time frame: from baseline to Week 48

  4. Changes from Baseline in Serum HBV DNA Levels during the Study Period

    Time frame: from baseline to Week 48

  5. Changes from Baseline in Serum HDV RNA Levels during the Study Period

    Time frame: from baseline to Week 48

  6. Changes from Baseline in Serum HBeAg Levels in HBeAg-positive Subjects at Screening

    Time frame: from baseline to Week 48

07

Study locations

1 site
  • First Hospital of Jilin University
    Changchun, Jilin 130021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jul 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2022
First posted
Jan 6, 2023
StartActual
Aug 11, 2021
Primary completionActual
Jul 25, 2022
CompletionActual
Jan 4, 2023
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05674448
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Aug 11, 2021
Primary completion
Jul 25, 2022
Completion
Jan 4, 2023
Last update
Oct 10, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Libevitug

Start the discussion